62 related articles for article (PubMed ID: 23097067)
21. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of pulmonary hypertension caused by left heart disease.
Xiao M; Lai D; Yu Y; Wu Q; Zhang C
Front Cardiovasc Med; 2023; 10():1079142. PubMed ID: 36937903
[TBL] [Abstract][Full Text] [Related]
23. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
[TBL] [Abstract][Full Text] [Related]
24. Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Villanueva DLE; Agustin RD; Llanes EJ
Cardiol Res; 2019 Dec; 10(6):369-377. PubMed ID: 31803335
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary Hypertension in General Cardiology Practice.
Calderaro D; Alves Junior JL; Fernandes CJCDS; Souza R
Arq Bras Cardiol; 2019; 113(3):419-428. PubMed ID: 31621783
[TBL] [Abstract][Full Text] [Related]
26. New perspectives and future directions in the treatment of heart failure.
Pellicori P; Khan MJI; Graham FJ; Cleland JGF
Heart Fail Rev; 2020 Jan; 25(1):147-159. PubMed ID: 31327116
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary Hypertension Due to Left Heart Disease: an Update.
Aras MA; Psotka MA; De Marco T
Curr Cardiol Rep; 2019 May; 21(7):62. PubMed ID: 31134443
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
29. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
Bermejo J; Yotti R; García-Orta R; Sánchez-Fernández PL; Castaño M; Segovia-Cubero J; Escribano-Subías P; San Román JA; Borrás X; Alonso-Gómez A; Botas J; Crespo-Leiro MG; Velasco S; Bayés-Genís A; López A; Muñoz-Aguilera R; de Teresa E; González-Juanatey JR; Evangelista A; Mombiela T; González-Mansilla A; Elízaga J; Martín-Moreiras J; González-Santos JM; Moreno-Escobar E; Fernández-Avilés F;
Eur Heart J; 2018 Apr; 39(15):1255-1264. PubMed ID: 29281101
[TBL] [Abstract][Full Text] [Related]
30. Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.
Xiong PY; Potus F; Chan W; Archer SL
Hypertension; 2018 Jan; 71(1):34-55. PubMed ID: 29158355
[No Abstract] [Full Text] [Related]
31. Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design).
Guglin M; Rajagopalan N; Anaya P; Charnigo R
Pulm Circ; 2016 Jun; 6(2):161-7. PubMed ID: 27252841
[TBL] [Abstract][Full Text] [Related]
32. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.
Dixon DD; Trivedi A; Shah SJ
Heart Fail Rev; 2016 May; 21(3):285-97. PubMed ID: 26714826
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.
Ferguson JE; Carson CC
Arab J Urol; 2013 Sep; 11(3):222-9. PubMed ID: 26558086
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
Jiang R; Wang L; Zhu CT; Yuan P; Pudasaini B; Zhao QH; Gong SG; He J; Liu JM; Hu QH
Hypertens Res; 2015 Dec; 38(12):829-39. PubMed ID: 26202179
[TBL] [Abstract][Full Text] [Related]
35. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
Pofi R; Gianfrilli D; Badagliacca R; Di Dato C; Venneri MA; Giannetta E
J Endocrinol Invest; 2016 Feb; 39(2):131-42. PubMed ID: 26142740
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary hypertension caused by pulmonary venous hypertension.
Kulik TJ
Pulm Circ; 2014 Dec; 4(4):581-95. PubMed ID: 25610595
[TBL] [Abstract][Full Text] [Related]
37. Novel drug targets in clinical development for heart failure.
George M; Rajaram M; Shanmugam E; VijayaKumar TM
Eur J Clin Pharmacol; 2014 Jul; 70(7):765-74. PubMed ID: 24710739
[TBL] [Abstract][Full Text] [Related]
38. Should there be sex-specific criteria for the diagnosis and treatment of heart failure?
Greiten LE; Holditch SJ; Arunachalam SP; Miller VM
J Cardiovasc Transl Res; 2014 Mar; 7(2):139-55. PubMed ID: 24214112
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Duarte JD; Hanson RL; Machado RF
Future Cardiol; 2013 May; 9(3):335-49. PubMed ID: 23668740
[TBL] [Abstract][Full Text] [Related]
40. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Cooper TJ; Guazzi M; Al-Mohammad A; Amir O; Bengal T; Cleland JG; Dickstein K
Eur J Heart Fail; 2013 Jan; 15(1):119-22. PubMed ID: 23097067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
